


Q3 YTD 2025 Highlights

"We have demonstrated strong momentum through the first nine months of 2025, with solid growth across all three therapeutic areas and increasing contributions from our rare liver disease franchise."




David Loew
Chief Executive Officer



Geographic Breakdown

Total sales by region: 2025




North America
35%
of total sales

Europe
39%
of total sales

RoW
26%
of total sales

In this map, Europe is defined as the E.U., the U.K., Iceland, Liechtenstein, Norway, and Switzerland.

Oncology +6.6%



Rare Disease +101.0%



Neuroscience +9.5%



Q3 Pipeline Progression

IPN10200: LANTIC Phase II in aesthetics delivering a first-in-class, long-acting clinical profile

Bylvay®: Japan approval for PFIC²

Cabometyx®: EU approval in NETs³

ImCheck acquisition⁴

Expanding the pipeline in Oncology:

Phase IIb/III ready asset in AML⁵

Performance covers the nine-month period to 30 September 2025 (YTD 2025) compared to the nine-month period to 30 September 2024 (YTD 2024)